Deep, focused future-generation sequencing has exposed that subclonal mutations (i.e., those present in just a fraction of tumor cells) could be detected for all driver genes and so are connected with swift disease development and inadequate outcome.11–13 This is especially related for TP53 mutations specified the fact that, as described below, C